Private Equity
Long Hill Capital, a Chinese venture firm, has closed its second fund at $265 million. Fund 2's limited partners include global pensions, endowments, foundations, financial institutions, family offices and fund of funds. Long Hill invests in technology-enabled healthcare and consumer companies.
3 min read · 23 July 2018
Burlington, Massachusetts-based Bone Biologics, a developer of orthobiologic products for domestic and international spine fusion markets, has closed $5.9 million funding. The investors were not named.
1 min read · 23 July 2018
New York City-based Click Therapeutics Inc, a provider of digital therapeutic solutions as prescription medical treatments, has raised $17 million in financing. Sanofi Ventures led the round.
1 min read · 23 July 2018
10 min read · 23 July 2018
Walden Riverwood Ventures is seeking to raise $325 million for its third fund, according to a regulatory filing, called WRV III. The firm is led by Executive Managing Directors Lip-Bu Tan, Michael Marks and Nicholas Brathwaite and makes early-stage investments in what it calls core technologies, such as robotics company Bossa Nova, AI open source provider H20.ai and cell researcher Berkeley Lights.
1 min read · 20 July 2018
1 min read · 20 July 2018
4 min read · 20 July 2018
4 min read · 20 July 2018
4 min read · 20 July 2018
San Carlos, California-based Allakos, a developer of antibodies that treat various eosinophil and mast cell related diseases, has raised about $128.4 million for its IPO after pricing its over 7.1 million shares at $18 per share. The stock began trading July 19, 2018 on the NASDAQ under the ticker symbol "ALLK." Goldman Sachs and Jefferies LLC are the lead underwriters. Allakos' pre-IPO backers include Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
1 min read · 19 July 2018
